Search Within

Alison Michele Schram

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (19)
  2. Meeting Abstract (15)
  3. Research Letter (1)
Groups
  1. Department of Medicine (35)
  2. Early Drug Development Service (35)
  3. Gynecologic Medicine Service (35)
  4. Sloan Kettering Institute Postdocs (35)
  5. Solid Tumor Oncology Division (35)
  6. GSK Faculty (30)

More Groups

People
  1. Alexander Drilon (22)
  2. David Hyman (21)
  3. Marc Ladanyi (13)
  4. Ryma Benayed (13)
  5. Barry Taylor (12)
  6. Jaclyn Hechtman (12)

More People

Years
  1. 2024 (3)
  2. 2022 (6)
  3. 2021 (4)
  4. 2020 (6)
  5. 2019 (7)
  6. 2018 (5)

More Years

Publications
  1. Cancer Research (6)
  2. Journal of Clinical Oncology (6)
  3. Cancer Discovery (5)
  4. Clinical Cancer Research (3)
  5. Nature Medicine (3)
  6. JCO Precision Oncology (2)

More Publications

Publishers
  1. American Association for Cancer Research (15)
  2. American Society of Clinical Oncology (8)
  3. Nature Publishing Group (7)
  4. American Society of Hematology (1)
  5. Cell Press (1)
  6. Elsevier Inc. (1)

More Publishers

Results (35)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer
    Meeting Abstract

    Marra, A.; Selenica, P.; Zhu, Y.; Safonov, A.; Razavi, P.; Roulston, A.; Koehler, M.; Curigliano, G.; Ross, D. S.; Weigelt, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
    Journal Article

    Walmsley, C. S.; Jonsson, P.; Cheng, M. L.; McBride, S.; Kaeser, C.; Vargas, H. A.; Laudone, V.; Taylor, B. S.; Kappagantula, R.; Baez, P.; more...
    npj Precision Oncology (2024)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Mechanisms of acquired resistance to TRK inhibitors
    Meeting Abstract

    Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study
    Meeting Abstract

    Burris, H. A. 3rd; Ulahannan, S. V.; Haura, E. B.; Ou, S. H. I.; Capasso, A.; Munster, P. N.; Kitai, H.; Wang, Z.; Hayes, J.; Tao, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Zenocutuzumab, a HER2XHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements
    Journal Article

    Schram, A. M.; Odintsov, I.; Espinosa-Cotton, M.; Khodos, I.; Sisso, W. J.; Mattar, M. S.; Lui, A. J. W.; Vojnic, M.; Shameem, S. H.; Chauhan, T.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • AKT mutant allele-specific activation dictates pharmacologic sensitivities
    Journal Article

    Shrestha Bhattarai, T.; Shamu, T.; Gorelick, A. N.; Chang, M. T.; Chakravarty, D.; Gavrila, E. I.; Donoghue, M. T. A.; Gao, J.; Patel, S.; Gao, S. P.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Spectrum of BRAF mutations and gene rearrangements in ovarian serous carcinoma
    Journal Article

    Chui, M. H.; Chang, J. C.; Zhang, Y.; Zehir, A.; Schram, A. M.; Konner, J.; Drilon, A. E.; da Cruz Paula, A.; Weigelt, B.; Grisham, R. N.
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save